A randomized, double-blind, placebo-controlled, multi-center phase 3 registrational study of larsucosterol in alcohol-associated hepatitis
Latest Information Update: 06 Apr 2025
At a glance
- Drugs Larsucosterol (Primary) ; Methylprednisolone
- Indications Alcoholic hepatitis
- Focus Registrational; Therapeutic Use
- Sponsors DURECT Corporation
Most Recent Events
- 26 Mar 2025 According to a DURECT Corporation media release, topline results expected within two years of trial initiation.
- 26 Mar 2025 According to a DURECT Corporation media release, data from AHFIRM study were presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH).
- 28 Jan 2025 event According to a DURECT Corporation media release, the company plan to initiate the trial in 2025, pending funding.